Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline. We now have 14 investigational RNAi-based medicines in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback